BARCELONA—A novel peptide-based erythropoiesis-stimulating agent (ESA) called Hematide safely raises hemoglobin levels in anemic CKD patients and maintains stable hemoglobin levels in hemodialysis patients who switch to the drug from epoetin alfa, data suggest.
BARCELONA—Pro-inflammatory cytokines are a marker for increased cardiovascular and overall mortality in dialysis patients, new research demonstrates.
BARCELONA—Once-monthly dosing of continuous erythropoietin receptor activator (C.E.R.A.) maintains stable hemoglobin levels in CKD patients regardless of age, gender, or comorbidities, according to study data presented here at the 44th Congress of the European Renal Association-European Dialysis and Transplant Association.
BARCELONA—Nocturnal hemodialysis (NHD) improves both cardiac and metabolic parameters and reduces the need for medication compared with conventional hemodialysis (CHD), according to a head-to-head comparison of the two modalities presented here at the 44th Congress of the European Renal Association-European Dialysis and Transplant Association.
GLASGOW—A European study confirms that overweight and obese patients have a survival advantage on hemodialysis when compared with normal-weight patients, researchers reported. Furthermore, a weight loss of 3% over the first year of dialysis was associated with a higher mortality rate compared with patients whose weight remained stable or who gained weight.